Clinical Trial Update: Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of lenalidomide, sunitinib, and cyclophosphamide for stage IV eye melanoma (intraocular and conjunctival melanoma) was terminated; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctival Melanoma
• Intraocular Melanoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Revlimid (lenalidomide)
• Sutent (sunitinib)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2012-11-14